- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07562256
Effects of Different Doses of Caffeine on Physical and Cognitive Performance in Female Handball Players
Dose-Dependent Effects of Acute Caffeine Ingestion on Physical and Cognitive Performance in Female Handball Players: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
This study investigates how different doses of caffeine affect physical and cognitive performance in female handball players. Caffeine is widely used as a performance-enhancing substance, but its effects may vary depending on the type of performance and the dose consumed.
In this randomized, double-blind, placebo-controlled crossover study, participants complete three experimental conditions: placebo, low-dose caffeine (3 mg/kg), and moderate-dose caffeine (6 mg/kg). Each participant receives all conditions in a randomized order, with sufficient time between sessions to avoid carryover effects.
The study evaluates three main performance domains relevant to team sports. Physical performance is assessed using an intermittent running test. Cognitive performance is measured using a reaction time task that evaluates attention and inhibitory control. In addition, a throwing test is used to assess sport-specific motor performance.
The main objective is to determine whether caffeine produces dose-dependent improvements and whether these effects differ across physical, cognitive, and technical performance domains. The findings aim to provide practical insights for athletes and coaches regarding optimal caffeine use in team sport settings.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Caffeine is one of the most widely consumed ergogenic aids in sport, known to influence both physiological and cognitive processes primarily through antagonism of adenosine receptors. Although its beneficial effects on endurance performance and alertness are well established, evidence regarding its effects on cognitive control and sport-specific technical skills remains inconsistent, particularly in team sport settings where multiple performance domains interact.
Team sports such as handball require the integration of intermittent high-intensity physical efforts, rapid decision-making, and precise motor execution. These components are not independent; instead, they compete for shared neurocognitive resources, especially under conditions of fatigue. As a result, interventions such as caffeine supplementation may exert domain-specific effects rather than uniform improvements across all aspects of performance.
Despite extensive research on caffeine, most studies have examined either physical or cognitive outcomes in isolation. Furthermore, dose-response relationships remain unclear, with previous findings suggesting that lower doses may be sufficient to enhance physical performance, whereas cognitive outcomes may require higher levels of stimulation. However, limited evidence exists on whether these dose-dependent effects are maintained when multiple performance domains are assessed within the same experimental framework.
The present study addresses this gap by simultaneously evaluating physical, cognitive, and sport-specific motor performance following different doses of caffeine in female handball players. A randomized, double-blind, placebo-controlled crossover design is used to minimize inter-individual variability and improve internal validity. Participants complete three experimental conditions (placebo, low-dose caffeine, and moderate-dose caffeine), each separated by an adequate washout period to reduce potential carryover effects.
The protocol includes standardized procedures to control for confounding factors such as time of day, environmental conditions, and prior physical activity. Testing sessions follow a fixed sequence, beginning with cognitive assessment, followed by a sport-specific throwing task, and concluding with an intermittent running test. This structure is designed to reflect the multi-component demands of team sport performance while maintaining methodological control.
The primary objective is to determine whether caffeine produces dose-dependent effects across different performance domains. Specifically, the study examines whether physical performance improvements occur at lower doses, whether cognitive performance shows greater sensitivity to higher doses, and whether technical motor performance responds differently to caffeine ingestion. By integrating these domains within a single experimental design, the study aims to provide a more ecologically valid understanding of caffeine's ergogenic effects in team sport contexts.
The findings are expected to contribute to evidence-based recommendations for caffeine use in athletes, emphasizing the importance of aligning supplementation strategies with specific performance goals rather than assuming uniform benefits across all domains.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Central
-
Sinop, Central, Turquie (Türkiye), 57100
- Sinop University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Female handball players
- Regular participation in competitive handball training
- Minimum of 3 years of handball training experience
- Free from musculoskeletal injury within the past 6 months
Exclusion Criteria:
- Known caffeine sensitivity or allergy
- Use of medications or supplements that may affect physical or cognitive performance
- Presence of cardiovascular disease
- Presence of metabolic disorders
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo Condition
Participants receive placebo capsules prior to testing in a randomized
|
Ingestion of identical capsules containing polydextrose with no active ingredient, administered 60 minutes prior to testing.
|
|
Expérimental: Low-Dose Caffeine
Participants receive 3 mg/kg caffeine prior to testing in a randomized
|
Acute ingestion of caffeine at a dose of 3 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.
|
|
Expérimental: Moderate-Dose Caffeine
Participants receive 6 mg/kg caffeine prior to testing in a randomized
|
Acute ingestion of caffeine at a dose of 6 mg per kilogram of body mass, administered in capsule form 60 minutes prior to testing.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Flanker Task Reaction Time
Délai: During each experimental session (60 minutes after supplementation)
|
Mean reaction time (ms) during correct trials in the Simplified Eriksen Flanker task, used to assess cognitive processing speed.
|
During each experimental session (60 minutes after supplementation)
|
|
Yo-Yo Intermittent Recovery Test Level 1 Distance
Délai: During each experimental session (60 minutes after supplementation)
|
Total distance covered during the Yo-Yo Intermittent Recovery Test Level 1, used to assess intermittent running performance.
|
During each experimental session (60 minutes after supplementation)
|
|
Throwing Velocity
Délai: During each experimental session (60 minutes after supplementation)
|
Mean ball velocity (km/h) measured during a standardized handball throwing test.
|
During each experimental session (60 minutes after supplementation)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Flanker Task Accuracy
Délai: During each experimental session (60 minutes after supplementation)
|
Percentage of correct responses in the Simplified Eriksen Flanker task.
|
During each experimental session (60 minutes after supplementation)
|
|
Flanker Effect
Délai: During each experimental session (60 minutes after supplementation)
|
Difference in reaction time between incongruent and congruent trials in the Flanker task.
|
During each experimental session (60 minutes after supplementation)
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine's effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016 Dec;71:294-312. doi: 10.1016/j.neubiorev.2016.09.001. Epub 2016 Sep 6.
- Guest NS, VanDusseldorp TA, Nelson MT, Grgic J, Schoenfeld BJ, Jenkins NDM, Arent SM, Antonio J, Stout JR, Trexler ET, Smith-Ryan AE, Goldstein ER, Kalman DS, Campbell BI. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021 Jan 2;18(1):1. doi: 10.1186/s12970-020-00383-4.
- Pickering C, Grgic J. Caffeine and Exercise: What Next? Sports Med. 2019 Jul;49(7):1007-1030. doi: 10.1007/s40279-019-01101-0.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SU-2025-688-CAF
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .